Search
Confirm
Cancel
News

News

Fusen Pharmaceutical Stock code:1652.HK
Location:
Homepage
-
-
-
Two TCM research centers inaugurated in Hengqin Guangdong Macao deep cooperation zone

Two TCM research centers inaugurated in Hengqin Guangdong Macao deep cooperation zone

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2022-06-28
  • Views:

(Summary description)

Two TCM research centers inaugurated in Hengqin Guangdong Macao deep cooperation zone

(Summary description)

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2022-06-28 17:51
  • Views:
Information


On June 17, the National Engineering and Technology Research Center for modernization of traditional Chinese medicine and Guangdong Provincial Engineering and Technology Research Center for disease susceptibility and research and development of traditional Chinese medicine set up branch centers in Hengqin Guangdong Macao deep cooperation zone (hereinafter referred to as the cooperation zone). The supporting units are Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Jiaheng pharmaceutical).


It is reported that the National Engineering and Technology Research Center for the modernization of traditional Chinese medicine is a backbone research center of the traditional Chinese medicine industry established with the approval of the Ministry of science and technology of the people's Republic of China and aimed at promoting the national action plan for the modernization of traditional Chinese medicine science and technology industry. Guangdong disease susceptibility and traditional Chinese medicine R & D engineering technology research center is a provincial laboratory established by Jinan University with the approval of Guangdong Provincial Department of science and technology. Relying on the two centers will improve the problem that Jiaheng medicine relies too much on a single variety in the industry. On the one hand, Jiaheng medicine plans to cultivate the company's exclusive variety of Li Qi into a large variety of traditional Chinese medicine; On the other hand, it will promote the cooperation between the company and universities, and accelerate the transformation of new scientific and technological achievements.


Caozhiming, President of Jiaheng pharmaceutical, said, "the implementation of these national and provincial research platforms is conducive to the transformation and industrialization of more Macao's scientific and technological achievements in traditional Chinese medicine in the cooperation zone, and to create a new demonstration of Macao's innovative development of traditional Chinese medicine."

Jiaheng pharmaceutical was established in the Hengqin Guangdong Macao cooperative traditional Chinese medicine science and Technology Industrial Park (hereinafter referred to as "the Industrial Park") in October, 2021. It is the first traditional Chinese medicine R & D platform settled in the industrial park and officially operated after the establishment of the cooperation zone. It is mainly positioned for the R & D and transformation of scientific and technological achievements of innovative traditional Chinese medicine and the secondary development of traditional Chinese medicine, chemical drug raw materials and preparations, light medical beauty products and great health products.

While building the above-mentioned national and provincial scientific research platforms, Jiaheng medicine has also established in-depth cooperative relations with well-known universities and scientific research institutions such as the University of Macao, the Macao University of science and technology, Jinan University and the Chinese Academy of traditional Chinese medicine. At the beginning of June this year, the company obtained the drug production license (commissioned production), which is the first holder of drug marketing license after the establishment of the cooperation zone.

Recently, Jiaheng pharmaceutical has also been approved to set up a branch of Hengqin postdoctoral scientific research workstation. Gaojiaying, the first doctor of traditional Chinese medicine from Macao, has entered the station and started scientific research. Gaojiaying said, "We support the development of the traditional Chinese medicine industry. The joint development of the great health industry with Hengqin has been written into Macao's" Five Year Plan ". In Hengqin, we can participate in more projects and become a witness for the builders of the development of the Great Bay Area".

Background information:

1、 National Engineering and Technology Research Center for modernization of traditional Chinese Medicine

The National Engineering and Technology Research Center for the modernization of traditional Chinese medicine is a backbone Research Center for the traditional Chinese medicine industry established with the approval of the Ministry of science and technology of the people's Republic of China to promote the national action plan for the modernization of traditional Chinese medicine science and technology industry. In 1996, the Ministry of science and technology, the State Administration of traditional Chinese medicine, the science and Technology Department of Guangdong Province, Zhuhai science and Technology Bureau, Lizhu Pharmaceutical Group and Guangzhou University of traditional Chinese medicine jointly funded the establishment of the National Engineering and Technology Research Center for the modernization of traditional Chinese medicine. Relying on Lizhu Pharmaceutical Group Co., Ltd. and Guangzhou University of traditional Chinese medicine, the competent departments are the State Administration of traditional Chinese medicine and the science and Technology Department of Guangdong Province.

2、 Guangdong disease susceptibility and TCM R & D Engineering Technology Research Center

Relying on the double first-class disciplines of the school of pharmacy of Jinan University, "985 innovative drug research advantage discipline platform", "Guangdong Provincial Key Laboratory of traditional Chinese medicine efficacy material basis and innovative drug research", and the "traditional Chinese medicine innovative drug discovery and modern innovation and talent introduction base" of the State Administration of foreign experts, It has long been committed to the research on the modernization of natural drugs and traditional Chinese medicine, and has carried out industry university research cooperation with many famous traditional Chinese medicine manufacturers inside and outside the province, revealing the scientific connotation of products and upgrading technical barriers. At present, the provincial engineering center has 23 formal staff, including 16 senior scientific research personnel. Among them, there are 1 academician of the Chinese Academy of engineering, 1 International collaborator of the people's Republic of China, 2 national outstanding young scholars, 2 winners of the national excellent natural science foundation, 2 young Yangtze River scholars and 2 distinguished professors of Pearl River scholars. It has formed a drug R & D team with multi-disciplinary mutual support, reasonable talent structure and rich in innovation. In the past five years, the engineering center has published more than 100 papers in NAT Chem Biol, NAT commun2) and other journals, authorized more than 60 patents, won a number of provincial and ministerial science and technology progress awards, and cultivated a number of young talents for traditional Chinese medicine research.

Related News

Fusen

Fusen pharmaceutical: metformin hydrochloride sustained release tablets passed the consistency evaluation

Fusen pharmaceutical metformin hydrochloride sustained-release tablets have successfully passed the evaluation of the consistency of quality and efficacy of generic drugs! Metformin Hydrochloride Sustained Release Tablets, a diabetes drug, has been approved by the State Administration for drug control. This product has successfully passed the quality and efficacy consistency evaluation of generic drugs, which is an authoritative recognition of the R & D capacity, production and quality management system and clinical efficacy of Fusen pharmaceutical, further highlights the product brand of Fusen pharmaceutical, helps to improve the market competitiveness of the drug, and accumulates valuable experience for the company's follow-up products to carry out generic drug consistency evaluation. ▲ notice of approval from the State Drug Administration Metformin Hydrochloride Tablets is the basic medicine for diabetes. It is used for diet and physical exercise to control type 2 diabetes patients with blood glucose inefficacy, especially obesity and hyperinsulinemia. As a first-line drug for the treatment of type II diabetes, metformin is often used in combination with other oral hypoglycemic agents. ▲ for medical professionals only Because of the superiority of metformin, it is listed as the first-line treatment for hypoglycemic treatment in the guidelines for prevention and treatment of type II diabetes, formulated by professional academic organizations both at home and abroad. As the holder of drug marketing license, Fusen pharmaceutical will not forget its original intention, forge ahead, strictly control the product quality, and constantly optimize the product layout, so that more drugs of Fusen pharmaceutical can benefit the majority of patients.
2022-04-26
Jiaheng

Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station

Recently, the Department of human resources and social security of Guangdong Province issued a notice that the National Postdoctoral Management Committee approved Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of Fusen pharmaceutical, to set up a postdoctoral scientific research workstation branch. ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. is a research and development subsidiary established by Fusen pharmaceutical in response to the national development strategy of traditional Chinese medicine. In order to enhance the independent research and development ability of traditional Chinese medicine, take the research and development of high-quality and effective traditional Chinese medicine as the main goal, and integrate the high-quality traditional Chinese medicine resources in the industry. ▲ Guangdong Macao science and Technology Industrial Park of traditional Chinese Medicine The company is located in Hengqin Guangdong Macao cooperative traditional Chinese medicine science and Technology Industrial Park. It is the first R & D platform settled in the industrial park and officially operated after the establishment of Hengqin Guangdong Macao deep cooperation zone. It is the supporting unit of the large variety cultivation sub center of traditional Chinese medicine of the national traditional Chinese medicine modernization engineering technology center. Its main business is the R & D of innovative traditional Chinese medicine and secondary development of traditional Chinese medicine, chemical medicine raw materials and preparations, light medicine and beauty products and great health products. This time, Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station, which is an affirmation of Jiaheng pharmaceutical's technological innovation ability and R & D ability, creates conditions for the company's talent training and the improvement of technological innovation ability, is conducive to further promoting the company's cooperation with universities and scientific research institutes, is conducive to the introduction of high-end R & D talents, is conducive to further improving the company's independent R & D ability and realizing the landing and transformation of scientific research achievements, Promote the sustainable innovation and development of the company and continuously improve the core competitiveness of the company.
2022-04-19

WeChat

福森药业

Copyright © 2021 Fusen Pharmaceutical Company Limited

豫ICP备2021028871号  Powered by www.300.cn

Copyright © 2021 Fusen Pharmaceutical  All Rights Reserved.      豫ICP备2021028871号        Powered by www.300.cn